CIBC Asset Management Inc Increases Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

CIBC Asset Management Inc increased its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 5.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,972 shares of the specialty pharmaceutical company’s stock after buying an additional 97 shares during the period. CIBC Asset Management Inc’s holdings in Jazz Pharmaceuticals were worth $243,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. UMB Bank n.a. lifted its position in shares of Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 129 shares in the last quarter. Ellsworth Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 0.4% during the 4th quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock valued at $4,675,000 after buying an additional 149 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Jazz Pharmaceuticals by 2.2% during the 4th quarter. Exchange Traded Concepts LLC now owns 7,045 shares of the specialty pharmaceutical company’s stock valued at $868,000 after buying an additional 155 shares in the last quarter. Cooper Financial Group lifted its position in shares of Jazz Pharmaceuticals by 3.7% during the 4th quarter. Cooper Financial Group now owns 4,334 shares of the specialty pharmaceutical company’s stock valued at $534,000 after buying an additional 156 shares in the last quarter. Finally, Coldstream Capital Management Inc. lifted its position in shares of Jazz Pharmaceuticals by 7.7% during the 3rd quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock valued at $259,000 after buying an additional 165 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the company. TD Cowen reduced their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Robert W. Baird increased their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research note on Monday, November 18th. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Finally, Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Buy” and an average target price of $180.33.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the sale, the chief executive officer now owns 425,525 shares in the company, valued at $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 5,053 shares of company stock worth $617,442. 4.20% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $139.67 on Wednesday. The stock has a 50-day simple moving average of $125.42 and a 200-day simple moving average of $118.44. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock has a market capitalization of $8.44 billion, a PE ratio of 19.67, a PEG ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $140.52.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.